EVALUATION OF THE ANTI-TUMOUR EFFECT OF BIOLOGICAL SCAFFOLD DERIVED FROM ADIPOSE TISSUE LOADED WITH THE CHEMOTHERAPEUTIC DRUGS [PN-III-P2-2.1-PED-2019-2893], director proiect Giulio Alessandri
| Project Title | Evaluation of the anti-tumour effect of biological scaffold derived from adipose tissue loaded with the chemotherapeutic drugs |
| Project Registration Code | PN-III-P2-2.1-PED-2019-2893 |
| Project Acronym | MADRE |
| Project Scope and Objectives | The aim of the project is to study an innovative anti-tumor therapy approach based on the use of human microfragmented fat tissue (MFAT) and its devitalized form (D-MFAT) obtained upon freezing /thawing procedure, as a biological support in combination with an anti-tumor drugs. Preliminary in vitro data have shown that both MFAT and D-MFAT can incorporate very high dose of anti-cancer drugs that are subsequently released in effective amounts able to induce tumor cell destruction if located nearby. On this basis the main objects of this project will be: a) to complete the morphological and structural organization of MFAT and D-MFAT as well their characterization in terms of proteins and cytokines content; b) to evaluate other systems of MFAT devitalization to produce new fat-derived biological scaffold for drug delivery; c) To establish MFAT and D-MFAT’s ability to incorporate (dosages), release (kinetic) anti-tumor drugs widely used in human oncology such as: Paclitaxel ( PTX), Doxorubicine (DX ) and Vincristine (VC) ; d) to determine their anti- tumor activity in vitro (co-culture with tumor cell lines) and in vivo in animals ( using immuno-deficient mice which are permissive to the growth of human cells) bearing human tumors such as HepG2, U87MG and CF-PAC-1; respectively HCC, GBM and Pancreatic Cancer. We expected that this study will give us sufficient information about the possibility to use MFAT or D-MFAT as a powerful natural scaffold for anti-cancer drug delivery and thus opening the possibility to treat those human tumors that are actually without an effective anti-cancer therapy. This study will be also important to obtain more information about MFAT and D-MFAT safety, necessary for a translation of these results in human clinical applications. |
| Project Start Date | 01/05/2020 |
| Project End Date | 30/04/2022 |
| Project Duration | 24 months |
| Total budget value | 599.748,00 lei |
| Team: | Giulio Alessandri -> PROJECT LEADER Mark Slevin -> Research member Adela Nechifor-Boila -> Research member Hamida Al Hussein -> Technician member Dia Alina Miron -> Research member Bogdan Cordos -> Technician member vacant position -> Postdoctoral member |
| Results | Deliverable 1: Preparations of MFAT and D-MFAT aliquots Deliverable 2: Characterization of materials and preparation and optimization of the in vitro tumour model using lines U87MG, CFPAC-1, HepG2-optimization of uptake and release and SOPs Deliverable 3: in vitro experiments: uploading of the drugs, evaluation of incorporation, release, anti-tumor activity, proliferation assays and determination of exact protocol for the in vivo study Deliverable – outcome of tumour development and understanding the effectiveness of the Lipogem -drug treatment Statistical data analysis and final results elaboration. Deliverable – output of publication and dissemination of results to the scientific coimmunity through international conference participation and media. |
| Host institution | George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures |